MARKET

NVTA

NVTA

Invitae
NYSE

Real-time Quotes | Nasdaq Last Sale

27.31
-0.43
-1.55%
After Hours: 27.25 -0.06 -0.22% 17:53 05/17 EDT
OPEN
27.32
PREV CLOSE
27.74
HIGH
27.80
LOW
26.51
VOLUME
3.06M
TURNOVER
--
52 WEEK HIGH
61.59
52 WEEK LOW
15.22
MARKET CAP
5.73B
P/E (TTM)
-6.9468
1D
5D
1M
3M
1Y
5Y
Driehaus Capital Management Llc Buys Baidu Inc, Vale SA, Relay Therapeutics Inc, Sells Advanced ...
GuruFocus News · 6h ago
Clear Perspective Advisors, LLC Buys First Trust Low Duration Mortgage Opportunities ET, ...
GuruFocus News · 1d ago
Aequim Alternative Investments LP Buys PG&E Corp, Workday Inc, Ford Motor Co, Sells MongoDB ...
GuruFocus News · 5d ago
Non-Invasive Prenatal Testing Market Investigation Reveals Enhanced Growth, Industry Developments, Current Trends By 2025
Japan, Japan, Tue, 11 May 2021 01:39:42 / Comserve Inc. / -- The report analyze market size, share, growth, trends, segmentation, top key players,...
Comserve · 6d ago
Invitae (NVTA) Outpaces Stock Market Gains: What You Should Know
Zacks.com · 05/07 21:50
--Morgan Stanley Adjusts Price Target on Invitae to $41 From $45, Maintains Equal-Weight Rating
MT Newswires · 05/06 12:51
Morgan Stanley Maintains Equal-Weight on Invitae, Lowers Price Target to $41
Morgan Stanley maintains Invitae (NYSE:NVTA) with a Equal-Weight and lowers the price target from $45 to $41.
Benzinga · 05/06 12:35
Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $48.53 million, in Skillz Inc (NYSE: SKLZ) on Wednesday.
Benzinga · 05/06 05:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVTA. Analyze the recent business situations of Invitae through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVTA stock price target is 47.40 with a high estimate of 58.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 439
Institutional Holdings: 190.67M
% Owned: 90.93%
Shares Outstanding: 209.68M
TypeInstitutionsShares
Increased
101
12.26M
New
54
2.55M
Decreased
73
5.18M
Sold Out
37
1.69M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Sean George
Chief Financial Officer
Shelly Guyer
Chief Operating Officer
Kenneth Knight
Chief Accounting Officer
Robert Werner
General Counsel/Secretary
Thomas Brida
Other
Robert Nussbaum
Other
Katherine Stueland
Other
Karthik Suri
Lead Director/Independent Director
Christine Gorjanc
Director
Kimber Lockhart
Director
Jason Myers
Independent Director
Eric Aguiar
Independent Director
Geoffrey Crouse
Independent Director
Chitra Nayak
No Data
About NVTA
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Webull offers kinds of Invitae Corp stock information, including NYSE:NVTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVTA stock methods without spending real money on the virtual paper trading platform.